CWM LLC boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 1.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 599,411 shares of the biopharmaceutical company's stock after purchasing an additional 6,110 shares during the period. CWM LLC's holdings in Bristol Myers Squibb were worth $36,558,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BMY. Thoroughbred Financial Services LLC grew its stake in shares of Bristol Myers Squibb by 1.1% in the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after acquiring an additional 190 shares in the last quarter. Marcum Wealth LLC grew its stake in shares of Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after acquiring an additional 193 shares in the last quarter. Leelyn Smith LLC grew its stake in shares of Bristol Myers Squibb by 0.5% in the 4th quarter. Leelyn Smith LLC now owns 47,699 shares of the biopharmaceutical company's stock worth $2,698,000 after acquiring an additional 215 shares in the last quarter. Heron Bay Capital Management grew its position in Bristol Myers Squibb by 2.1% during the fourth quarter. Heron Bay Capital Management now owns 10,795 shares of the biopharmaceutical company's stock valued at $611,000 after buying an additional 220 shares during the period. Finally, Providence Capital Advisors LLC grew its position in Bristol Myers Squibb by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 52,480 shares of the biopharmaceutical company's stock valued at $2,968,000 after buying an additional 221 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
Bristol Myers Squibb Price Performance
BMY traded up $0.73 on Wednesday, reaching $47.16. The company had a trading volume of 13,248,827 shares, compared to its average volume of 12,808,637. The business has a 50 day simple moving average of $47.43 and a 200 day simple moving average of $53.10. The company has a market cap of $95.98 billion, a price-to-earnings ratio of 17.66, a P/E/G ratio of 2.39 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. Bristol Myers Squibb Company has a 52-week low of $41.20 and a 52-week high of $63.33.
Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same period last year, the firm posted ($4.40) earnings per share. Bristol Myers Squibb's quarterly revenue was down 5.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.
Bristol Myers Squibb Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.26%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.
Insider Buying and Selling
In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president directly owned 83,513 shares of the company's stock, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 0.09% of the stock is owned by insiders.
Analyst Upgrades and Downgrades
BMY has been the subject of several research reports. UBS Group reduced their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Jefferies Financial Group reduced their price target on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research report on Wednesday, April 23rd. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Morgan Stanley dropped their price objective on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a report on Thursday, July 10th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $57.69.
View Our Latest Report on Bristol Myers Squibb
About Bristol Myers Squibb
(
Free Report)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
Before you consider Bristol Myers Squibb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.
While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
